Browse
Explore conditions, clinical trials, and the organisations running them.
Never miss a new study
Get alerted when new trials match your condition
Sign up free to track the conditions you care about and get a personal digest when new trials appear.
By submitting, you agree to our Terms of use
116076 trials found · Page 258 of 5804
-
New CAR t therapy targets two proteins to fight blood cancers
Disease control Not yet recruitingThis study is to provide locally produced, bispecific CD19 CD20 CAR T cells to patients with B-cell lymphoma/leukemia who have no access to commercial CAR T cells or who have relapsed thereafter. The primary objective is to assess the safety of bispecific anti-CD19, anti- CD20 CA…
Phase: PHASE1 • Sponsor: University Hospital, Basel, Switzerland • Aim: Disease control
Last updated Jun 27, 2026 08:06 UTC
-
New drug cocktail aims to outsmart lung cancer resistance
Disease control Not yet recruitingProtocol Title A Study to Evaluate ANS014004 in Combination with EGFR-TKI in Patients with EGFR Mutation-Positive Locally Advanced or Metastatic Non-Small Cell Lung Cancer The main purpose of this research study is to Find a safe and tolerable dose of two investigational drugs…
Phase: PHASE1, PHASE2 • Sponsor: Beijing Pearl Biotechnology Limited Liability Company • Aim: Disease control
Last updated Jun 27, 2026 08:04 UTC
-
New combo therapy aims to treat leukemia without harsh chemo
Disease control Not yet recruitingThe purpose of this study is to find out whether combining inotuzumab and blinatumomab is a safe and effective treatment for participants with newly diagnosed B-cell acute lymphoblastic leukemia (B-ALL).
Phase: PHASE1, PHASE2 • Sponsor: Memorial Sloan Kettering Cancer Center • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
Personalized cancer treatment: matching drugs to tumor DNA may delay disease worsening
Disease control Not yet recruitingThe goal of this clinical trial is to learn if drugs that are matched to tumor DNA mutations work to treat metastatic solid cancers in adults. The main questions it aims to answer are: Is tumor worsening delayed for a longer period of time if patients take drugs that match DNA m…
Phase: PHASE2 • Sponsor: University of California, San Diego • Aim: Disease control
Last updated Jun 27, 2026 12:05 UTC
-
New surgery aims to stop debilitating arm swelling in breast cancer patients
Disease control Not yet recruitingLymphedema is a devastating complication of breast cancer surgery that decreases the quality of life of up to 40% of breast cancer survivors. Most lymphedema in breast cancer patients is because lymphatics shared between the axilla and the arm are sacrificed during axillary lymph…
Phase: NA • Sponsor: Case Comprehensive Cancer Center • Aim: Disease control
Last updated Jun 27, 2026 09:06 UTC
-
New drug cocktail aims to shrink liver tumors for surgery
Disease control Not yet recruitingThis study is a single-center, prospective, randomized, single-arm phase II clinical trial designed to evaluate the safety and efficacy of FULIRI chemotherapy regimen combined with targeted therapy (bevacizumab/cetuximab) as first-line conversion therapy for colorectal cancer wit…
Phase: PHASE2 • Sponsor: Zhongnan Hospital • Aim: Disease control
Last updated Jun 27, 2026 12:04 UTC
-
New drug cocktail takes aim at tough lung cancer
Disease control Not yet recruitingThis is a Phase Ib/II, open-label clinical study designed to evaluate the safety, tolerability, preliminary anti-tumor activity, recommended Phase 2 dose (RP2D), pharmacokinetic (PK) characteristics, and immunogenicity of DXC006 in combination with an immune checkpoint inhibitor …
Phase: PHASE1, PHASE2 • Sponsor: Hangzhou DAC Biotechnology Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 13:00 UTC
-
New study aims to stop Post-Surgery brain fog in seniors
Prevention Not yet recruitingNeurocognitive complications, mainly delirium and neurocognitive disorders, are common cerebral complications in older patients after surgery and associated with worse outcomes. In previous studies, perioperative use of dexmedetomidine-esketamine combination improved analgesia an…
Phase: PHASE4 • Sponsor: Peking University First Hospital • Aim: Prevention
Last updated Jun 27, 2026 12:31 UTC
-
Could a drug combo let some esophageal cancer patients skip surgery?
Disease control Not yet recruitingThis is a prospective, single-center, randomized phase 2 study of adebrelimab plus full-course neoadjuvant therapy in resectable locally advanced esophageal squamous cell carcinoma. Patients achieving clinical complete response (cCR) after neoadjuvant treatment will be randomized…
Phase: PHASE2 • Sponsor: Tianjin Medical University Cancer Institute and Hospital • Aim: Disease control
Last updated Jun 27, 2026 12:32 UTC
-
New model may predict and prevent deadly transplant complication
Disease control Not yet recruitingThis study aims to evaluate the efficacy of prophylactic ruxolitinib in adult patients at intermediate-to-high risk of severe acute GvHD, as predicted by the daGOAT model.
Phase: PHASE3 • Sponsor: Institute of Hematology & Blood Diseases Hospital, China • Aim: Disease control
Last updated Jun 27, 2026 12:33 UTC
-
AI could revolutionize heart disease screening in poor regions
Diagnosis Not yet recruitingThe main goal of this project is to see if RADAR (Rapid AI-assisted Detection and Analysis of Rheumatic heart disease), which is a machine and deep-learning AI model, can help make rheumatic heart disease (RHD) screening easier to expand. Specifically, the project will test wheth…
Phase: NA • Sponsor: Children's Hospital Medical Center, Cincinnati • Aim: Diagnosis
Last updated Jun 27, 2026 12:38 UTC
-
New scan could spot hidden prostate cancer spread
Diagnosis Not yet recruitingThe investigators are imaging patients with newly diagnosed prostate cancer using a new Positron Emission Tomography (PET) imaging agent (68Ga-NYM032) in order to evaluate the safety and diagnostic performance.
Phase: PHASE3 • Sponsor: Norroy Bioscience Co., LTD • Aim: Diagnosis
Last updated Jun 27, 2026 13:00 UTC
-
Could a common vitamin a drug tame a deadly immune storm?
Disease control Not yet recruitingThis study is designed to evaluate the safety and preliminary efficacy of all-trans retinoic acid (ATRA) as an initial treatment for patients with active hemophagocytic lymphohistiocytosis (HLH). HLH is a severe hyperinflammatory syndrome caused by excessive activation of immune …
Phase: PHASE2, PHASE3 • Sponsor: Beijing Anzhen Hospital • Aim: Disease control
Last updated Jun 27, 2026 13:02 UTC
-
Could a diabetes drug tame asthma in overweight kids?
Disease control Not yet recruitingThe goal of this clinical trial is to learn if metformin can improve asthma control in overweight and obese children with mild, moderate, or severe asthma. It will also evaluate the safety and metabolic effects of metformin in this population. The main questions the study aims to…
Phase: PHASE3 • Sponsor: Prof Ibrahim Janahi • Aim: Disease control
Last updated Jun 27, 2026 13:00 UTC
-
New combo aims to fix transfusion failure in blood cancer patients
Disease control Not yet recruitingPlatelet transfusion refractoriness (PTR) is a common complication in patients with hematological malignancies. It not only prolongs the duration of platelet transfusion dependence and significantly increases the risk of bleeding, but is also strongly associated with graft failur…
Phase: PHASE3 • Sponsor: The First Affiliated Hospital of Soochow University • Aim: Disease control
Last updated Jun 27, 2026 13:04 UTC
-
New probe technique could slash cervical cancer risk in HIV-Positive women
Prevention Not yet recruitingCervical cancer disproportionately affects women in low- and middle-income countries (LMICs), particularly women living with HIV (WLWH) who have a 6-fold increased risk of cervical cancer compared to women in the general population. Thermal ablation (TA) is recommended by the Wor…
Phase: NA • Sponsor: Fred Hutchinson Cancer Center • Aim: Prevention
Last updated Jun 27, 2026 13:06 UTC
-
New drug combo targets Tough-to-Treat myeloma
Disease control Not yet recruitingThis is a single-arm, open-label study to evaluate the efficacy and safety of CM336 combined with SOC therapy in patients with dynamically high-risk multiple myeloma.
Phase: PHASE2 • Sponsor: Institute of Hematology & Blood Diseases Hospital, China • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
Electric pulses aim to tame type 2 diabetes
Disease control Recruiting nowexperiment design: Single-center, single-arm, open-label trial Inclusion Criteria: 1. Ages 18-70. 2. At least 6 months prior to enrollment, the patient must have been diagnosed with type 2 diabetes mellitus. 3. The glycated hemoglobin level is 7.5%-10.5%. 4. BMI 2 7-40 kg/m2. 5…
Sponsor: Shanghai East Hospital • Aim: Disease control
Last updated Jul 03, 2026 00:00 UTC
-
Smart bomb for kidney cancer: imaging and radiation combo targets tough tumors
Disease control Recruiting nowThis is an open-label, multicenter, Phase 1a/1b study evaluating the theranostic pair 64Cu-PD-32766 Injection (PD-32766D) and 225Ac-PD-32766 Injection (PD-32766T) in adult patients with relapsed or refractory Carbonic Anhydrase IX (CA9)-expressing clear cell renal cell carcinoma …
Phase: PHASE1 • Sponsor: PeptiDream Inc. • Aim: Disease control
Last updated Jul 09, 2026 00:00 UTC
-
Engineered immune cells take on incurable blood cancer
Disease control Recruiting nowThe treatment options for multiple myeloma have evolved significantly over the years, providing patients with a range of therapies tailored to their specific circumstances. The choice of treatment often hinges on various factors, including the aggressiveness of the disease, indiv…
Phase: PHASE2 • Sponsor: Dr. Zaineb Akram • Aim: Disease control
Last updated Jul 10, 2026 00:00 UTC